Dearman, the clean cold technology company, welcomed Rt Hon Tom Brake to its new Clean Cold Technology Centre, ahead of a formal site launch in September.
The MP for Carshalton and Wallington visited the facility in Croydon, which is the first dedicated liquid air engine research and development hub in the UK, as the final fit-out was in progress. The facility houses four purpose-built test cells, labs and a workshop, and is home to Dearman’s 50-strong staff of engineers and analysts.
During the visit, Dearman’s engineering team demonstrated the company’s revolutionary zero-emission engine, which is powered by liquid nitrogen and generates both power and cooling. The engine is at the core of Dearman’s cutting-edge technologies, which have applications in transport and the built environment.
Dearman’s applications will have a positive impact on air quality and climate change, by providing a cost-effective alternative to diesel systems and helping to significantly reduce emissions of CO2, NOx and particulate matter.
Tom Brake, MP, said: “The work Dearman are doing developing an alternative to fossil fuels is fundamental in moving us forward as a greener country and will help create jobs here in the UK. I learned a great deal about the technology behind their invention and it is fantastic to see that the company has chosen to locate here and is continuing to grow.”
Michael Ayres, Deputy Chief Executive, Dearman, commented following the visit: “We were glad to welcome Tom Brake to the Dearman Technology Centre, and were delighted that he took such an interest in our work. In the coming years, Dearman will generate job opportunities in the immediate area, all of which will support the global roll-out of our clean cold technologies. As members of the community, we look forward to delivering technologies that will have a positive and immediate impact on air quality in the local area and around the world.”
Dearman’s first application, a zero-emission transport refrigeration system, is currently undergoing extended on-vehicle testing and will begin commercial trials later this year.